Measles Surging As Vaccine Rates Drop

Key Takeaways

• US measles cases hit 2,288 in 2025, highest since 1991
• 92% of US cases occur in unvaccinated individuals
• Bangladesh reported 166 measles deaths, mostly children under 2
• Vaccine coverage below 95% erodes herd immunity, prompting outbreaks
• COVID backlash and political misinformation accelerate MMR uptake decline

Pulse Analysis

The United States is confronting a measles resurgence that eclipses any outbreak seen in the past three decades. In 2025, the nation recorded 2,288 confirmed cases, and early 2026 figures suggest the trend will continue upward. The data reveal a stark disparity: 92% of U.S. infections are among the unvaccinated, even though fully immunized individuals outnumber the unvaccinated by roughly 23 to 1. Across the globe, Bangladesh is experiencing a parallel crisis, with nearly 3,000 laboratory‑confirmed cases and 166 child deaths, highlighting how low coverage can precipitate fatal outcomes in vulnerable populations.

Epidemiologists warn that dropping below the 95% MMR coverage threshold dismantles herd immunity, allowing the virus to find enough susceptible hosts to sustain transmission. The U.S. lost its measles elimination status in recent years, a designation that requires a full year without endemic spread. The decline in vaccine uptake is linked to the COVID‑19 pandemic’s erosion of trust in public‑health institutions, amplified by high‑profile anti‑vaccine figures and politicized rhetoric. This confluence of misinformation and policy resistance has created pockets of susceptibility that fuel outbreaks and strain local health resources.

Reversing the trend will require coordinated federal and state campaigns that address both logistical barriers and misinformation. Targeted outreach in communities with low uptake, coupled with transparent communication about vaccine safety, can rebuild confidence. Moreover, investing in surveillance and rapid response teams will help contain clusters before they threaten national elimination status. The economic stakes are significant: each outbreak incurs direct medical costs and indirect productivity losses, reinforcing the imperative to restore robust MMR coverage nationwide.